As of 2025-05-25, the Fair Value of Tekla Life Sciences Investors (HQL) is 73.61 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 12.35 USD, the upside of Tekla Life Sciences Investors is 496.00%.
With the market price of 12.35 USD and our fair value calculation, Tekla Life Sciences Investors (HQL) is a good investment. Investing in HQL stocks now will result in a potential gain of 496.00%.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 5Y Avg | |
| Net income | 123.05 | 64.53 | -104.60 | 22.35 | 85.00 | 38.07 |
| YoY growth | 274.59% | -47.56% | -262.10% | 121.37% | 280.27% | 73.32% |
| Market Cap (mil) | 356.54 |
| P/E | 4.19x |
| Forward P/E | 5.45x |
| EPS | 2.94 |
| Avg earnings growth rate | 73.32% |
| TTM earnings | 85.00 |